Member Info for jayhayes

Time to ask wallbrook

https://www.nsmedicaldevices.com/analysis/medical-devices-industry-2021/#

Ftse100? Oh god

https://health.economictimes.indiatimes.com/amp/news/diagnostics/auto-validation-of-diagnosis-and-touchless-inventory-are-promising-trends-that-can-deliver-high-standards-dr-kanav-kahol-ceo-divoc-labs/80051488?__twitter_impression=true

Thanks bigAL

Just reading Julys trading update........

The Company has pathogen detection orders to fulfil for the US DoD and is confident of first half sales of both Genedrive(R) units and assays to this customer. As previously announced the expectation remains to sign a new contract with the US DoD in autumn 2020 and achieve new sales volumes following commencement of their new fiscal year.

Despite some initial concerns around the impact of lockdown on the Antibiotic Induced Hearing Loss (AIHL) project, the NHS evaluation programme has continued to run during the past few months. After a slow period, the programme pace has increased somewhat as lock-down measures have eased and the Company remains optimistic of completing the project and achieving the Autumn 2020 timeframe for commercial launch with Inspiration Healthcare Plc.

I’m having doubts on the eu deal

Yep the 1 percent is all down to you well done big lad

Someone turn off and on the sp. seams stuck

Yes we are

Looks like it doesn’t it... troll

Sooooo this price action is a little boring

6 month cycle... wow

Q56: Do you expect the European sales with the highlighted MoH to be realised this calendar year?

Sales yes, but delivery/revenue recognition is for the new calendar year
Q57

I’ve heard that excuse soooo many times

Still ticking up nicely I see....

In its trading statement dated 1 August 2013, the Company advised shareholders that it was in discussions with Becton Dickinson ("BD") for an expansion of the supply and distribution agreement of its TB test which, if successful, would lead to additional revenues for the year ended 30 June 2013 of £1.0m - £1.2m being recognised. The Company today advises that the discussions with BD have not been successfully concluded and the supply and distribution agreement originally entered into in August 2012 has been terminated. The previous guidance for the results for the year ended 30 June 2013 of revenues of £5.4m (2012: £5.6m) and a loss after tax of £1.2m (2012: £0.2m) remains unchanged. Development of Genedrive® has been the key focus of the Personalised Medicine division, with Preclinical Research Services and Novel Therapies broadly in line with the prior year. Net cash as at 6 September 2013 was £6.1m. This will be reduced to £5.5m post the repayment of $1m to BD under the terms of the original agreement.

Found the nose dive....... hopefully we don’t get this from bc etc

Can anyone tell me why we was trading @ £5.82 in 2013 and every since its been dead? To go from that to 9p just before last march? I would be crying if I owned this company.

Ticking up nicely.... think you may have something else on your screen..... same thing that’s happened constantly recently we will go up .5 then down .5 ticking up nicely haha Jesus

Didn’t happens ffs